



PATENT
Attorney Docket No. SCRI1180-3

TECH CENTER 1600/2900

APR 04 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Griffin, et al. Art Unit: 1743
Serial No.: 09/606,779 Examiner: D. Saunders
Filed: June 28, 2000
Title: METHOD FOR DIAGNOSIS OF THROMBOTIC DISORDERS

Commissioner of Patents
Washington, D.C. 20231

AMENDMENT IN RESPONSE TO THE OFFICE ACTION

Responsive to the Office Action mailed September 13, 2001 (Paper No. 7), entry of the amendments and consideration of the following remarks are respectfully requested.

RECEIVED
MAR 27 2002
TC 1700

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on March 12, 2002, in an envelope addressed to:
Commissioner for Patents, Washington, D.C. 20231

Karen LePari

Karen LePari

In re Application of:
Griffin, et al.
Serial No.: 09/606,779
Filed: June 28, 2000
Page 2

PATENT
Attorney Docket No.: SCRIP1180-2

TECH CENTER 1600/2900

APR 04 2002

RECEIVED

I. AMENDMENTS

In the Specification:

In the specification, please delete the related application data and substitute the following rewritten paragraph:

a1 -- This application is a continuation and claims the benefit of priority under 35 USC § 120 of U.S. application Serial No. 09/189,343, filed November 10, 1998, now U.S. Patent No. 6,083,757; which is a continuation of U.S. application Serial No. 08/993,664, filed December 18, 1997, now U.S. Patent No. 5,834,223; which is a divisional of U.S. application Serial No. 08/339,828, filed November 14, 1994, now U.S. Patent No. 5,705,395. The disclosures of the prior applications are considered part of and are incorporated by reference in their entirety in the disclosure of this application.--

In the Claims:

✓
Please cancel claim 1 without prejudice.

Please add the following new claims:

a2 --2. An in vitro method for diagnosing a subject as having or as being at risk for having a thrombotic disorder associated with activated protein C (APC)-resistant factor V or Va, wherein the subject is presently on an oral anticoagulant regimen, the method comprising:

a) contacting a test sample comprising a coagulation factor V or Va-containing specimen from the subject with a procoagulant reagent, factor V-deficient plasma to provide coagulation factors other than factors V or Va, calcium present in a concentration from about 5 mM to 15 mM, and APC present at from about 100 ng/ml to 10 ug/ml in a test reaction; and